Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)

Hadassah Medical Center

Status: Completed

Conditions: Attention Deficit Hyperactivity Disorder

Treatments: Dietary Supplement: Placebo; Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA)

Study type: Interventional

Funder types: Other

Identifiers

NCT00874536

GDR3-HMO-CTIL

Details and patient eligibility

About

It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.

Enrollment: 40 patients

Sex: All

Ages: 6 to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ADHD diagnosis
• informed consent

Exclusion criteria

• refusal of any testing
• any comorbidities
• any medication or supplement use

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

ALA

Experimental group

Description:

This group will receive the ALA supplement

Treatment:

Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA)

Placebo

Placebo Comparator group

Description:

This group will receive the placebo supplement

Treatment:

Dietary Supplement: Placebo